ClinicalTrials.gg
CompletedNCT01148511SALUTEUpdated May 30, 2013Results posted

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)

A Phase 4 interventional study of Ranibizumab 0.5 mg in Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Turkey. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-05-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
50th of 124
99 · median 64
Started
2010
with 9 others
Phase 4
33 of 125
none open now
Registered
53rd of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 50th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2010, is one of 33 in phase 4, and was the 53rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD). The first treatment regimen was the approved AMD treatment of 1 injection each month for 3 months and than re-treatment of patients who have a visual loss of more than 5 letters with monthly control (Treat and Observe). The second treatment regimen was 1 injection each month for 3 months and than extending the control period if the macula is dry during the monthly control (Treat and Extend). If the "Treat and Extend" regimen is found effective and safe, the number of ranibizumab injections, the number of patient visits, the risk of adverse events due to the intravitreal injections, and policlinic occupation number could all be reduced.

03

Conditions studied

  • Age-related Macular Degeneration

Keywords

  • Macula degeneration
  • Ranibizumab
  • Choroidal neovascularisation
  • Treat and extend
  • Treat and observe
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients over the age of 50.
  • Patients with primary, secondary, or recurrent subfoveal choroidal neovascularization (CNV) to AMD with classic, minimal classic, or occult lesions.
  • Patients with CNV area ≥ %50 of the total lesion.
  • Total lesion area ≤ 12 disc areas for minimal classic/occult lesions and ≤ 9 disc areas for the classic lesions.
  • Best-corrected visual acuity (BCVA) score between 73 and 34 letters in the study eye.

Exclusion criteria

Exclusion Criteria:

  • BCVA \< 34 letters.
  • Patients using anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, , or protein kinase C inhibitors, etc) or inclusion in another trial (for any eye).
  • Verteporphin, external radiational therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy application to the eye before the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Treat and Extend

    Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.

    Drug: Ranibizumab 0.5 mg

  • Active comparator
    Treat and Observe

    Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.

    Drug: Ranibizumab 0.5 mg

Interventions

  • Ranibizumab was supplied as a sterile solution in sealed glass vials.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12

    Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there are 5 letters per line, the total score for a line on the logMAR chart represents a change of 0.1 log units. The formula for calculating the logMAR BCVA score is: 0.1 + logMAR value of the best line read - 0.02 x number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

    Time frame: Baseline to Month 12

  2. Change in Letter Count From Baseline to Month 12

    Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. A higher letter count score indicates better vision. A negative change score indicates improvement.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Letter Count From Baseline to Month 12

    Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Results are reported in various categories of change in letter count.

    Time frame: Baseline to Month 12

  2. Number of Visits

    Time frame: Baseline to Month 12

  3. Follow-up Duration

    Follow-up duration was defined as the number of days from Baseline to study discontinuation.

    Time frame: Baseline to Month 12

  4. Change in Central Retinal Thickness From Baseline to Month 12

    Retinal thickness was measured using Optical Coherence Tomography (OCT).

    Time frame: Baseline to Month 12

  5. Quality of Life

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Visits 2, 6, 9, 12, and 15. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function.

    Time frame: Visits 2, 6, 9, 12, and 15 (up to 12 months)

07

Results

Posted May 20, 2013

Participant flow

Exposed to Study Drug
Participant flow — Exposed to Study Drug
MilestoneAll PatientsTreat and ExtendTreat and Observe
Started9900
Completed9300
Not completed600
Withdrew: Protocol violation200
Withdrew: Lost to follow-up400
Randomized
Participant flow — Randomized
MilestoneAll PatientsTreat and ExtendTreat and Observe
Started04845
Completed03839
Not completed0106
Withdrew: Adverse event010
Withdrew: Protocol violation021
Withdrew: Lost to follow-up011
Withdrew: Consent withdrawal053
Withdrew: Other011

Outcome measures

PrimaryChange in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12

Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there are 5 letters per line, the total score for a line on the logMAR chart represents a change of 0.1 log units. The formula for calculating the logMAR BCVA score is: 0.1 + logMAR value of the best line read - 0.02 x number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.

Time frame:
Baseline to Month 12
Reported as:
Median · logMAR
Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12
logMARTreat and ExtendTreat and Observe
Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12-0.18 (-0.88 to 0.76)-0.12 (-0.88 to 1.56)
PrimaryChange in Letter Count From Baseline to Month 12

Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. A higher letter count score indicates better vision. A negative change score indicates improvement.

Time frame:
Baseline to Month 12
Reported as:
Median · Letters
Change in Letter Count From Baseline to Month 12
LettersTreat and ExtendTreat and Observe
Change in Letter Count From Baseline to Month 12-9 (-44 to 38)-6 (-44 to 78)
SecondaryLetter Count From Baseline to Month 12

Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Results are reported in various categories of change in letter count.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of patients
Letter Count From Baseline to Month 12
Percentage of patientsTreat and ExtendTreat and Observe
< 35 letters7.97.7
≥ 35 letters92.192.3
loss > 15 letters10.510.3
loss ≤ 15 letters or gained letter89.589.7
loss ≥ 30 letters2.65.1
loss < 30 letters or gained letter97.494.9
gain ≥ 0 letter76.361.5
Loss23.738.5
gain ≥ 15 letter34.223.1
gain < 15 letters or loss65.876.9
SecondaryNumber of Visits
Time frame:
Baseline to Month 12
Reported as:
Median · Visits
Number of Visits
VisitsTreat and ExtendTreat and Observe
Number of Visits12.0 (10.0 to 15.0)15.0 (12.0 to 15.0)
SecondaryFollow-up Duration

Follow-up duration was defined as the number of days from Baseline to study discontinuation.

Time frame:
Baseline to Month 12
Reported as:
Mean · Days
Follow-up Duration
DaysTreat and ExtendTreat and Observe
Follow-up Duration364.5 (310.0 to 396.0)366.0 (320.0 to 386.0)
SecondaryChange in Central Retinal Thickness From Baseline to Month 12

Retinal thickness was measured using Optical Coherence Tomography (OCT).

Time frame:
Baseline to Month 12
Reported as:
Median · µm
Change in Central Retinal Thickness From Baseline to Month 12
µmTreat and ExtendTreat and Observe
Change in Central Retinal Thickness From Baseline to Month 1288.5 (-190.0 to 584.0)61.0 (-470.0 to 500.0)
SecondaryQuality of Life

The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Visits 2, 6, 9, 12, and 15. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function.

Time frame:
Visits 2, 6, 9, 12, and 15 (up to 12 months)
Reported as:
Median · Units on a scale
Quality of Life
Units on a scaleTreat and ExtendTreat and Observe
Visit 270.0 (57.0 to 87.0)73.0 (62.0 to 89.0)
Visit 671.0 (65.0 to 83.0)69.5 (60.0 to 79.0)
Visit 969.0 (63.0 to 80.0)72.5 (62.0 to 92.0)
Visit 1272.0 (64.0 to 84.0)71.0 (60.0 to 91.0)
Visit 1569.0 (64.0 to 80.0)70.5 (57.0 to 85.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treat and Extend—5/48 (10.4%)10/48 (20.8%)
Treat and Observe—3/45 (6.7%)8/45 (17.8%)
Before Randomization—2/6 (33.3%)1/6 (16.7%)
Most frequent serious events
Most frequent serious events
EventTreat and ExtendTreat and ObserveBefore Randomization
ArrhythmiaCardiac disorders0/480/451/6
AzotemiaRenal and urinary disorders0/480/451/6
Mitral valve incompetenceCardiac disorders0/481/450/6
Aphasia SyncopePsychiatric disorders0/481/450/6
Vascular graftSurgical and medical procedures1/481/450/6
DiarrheaGastrointestinal disorders1/480/450/6
Lower and upper limb fractureMusculoskeletal and connective tissue disorders1/480/450/6
AsthmaRespiratory, thoracic and mediastinal disorders1/480/450/6
Herpes zosterSkin and subcutaneous tissue disorders1/480/450/6
Most frequent other events
Most frequent other events
EventTreat and ExtendTreat and ObserveBefore Randomization
InfluenzaRespiratory, thoracic and mediastinal disorders8/485/450/6
HypertensionVascular disorders1/482/451/6
Adenoviral conjunctivitisEye disorders2/483/450/6

Baseline characteristics

Safety population: All patients who received study drug (n=99). Not all patients who received study drug were randomized into the 2 treatment groups (n=93) due to discontinuation from the study in the first Period of the study. Baseline Characteristics are only reported for the randomized (n=93) patients.

Age Continuous
Age Continuous(years)Treat and ExtendTreat and ObserveTotal
Mean70.8 ± 8.871.1 ± 8.470.9 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Treat and ExtendTreat and ObserveTotal
Female232043
Male252550
08

Study locations

8 sites
  • Novartis Investigative Site
    Adana, Turkey
  • Novartis Investigational Site
    Ankara, Turkey
  • Novartis Investigative Site
    Ankara, Turkey
  • Novartis Investigative Site
    Bursa, Turkey
  • Novartis Investigative Site
    Eskişehir, Turkey
  • Novartis Investigative Site
    İstanbul, Turkey
  • Novartis Investigative Site
    İzmir, Turkey
  • Novartis Investigative Site
    Konya, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2010
First posted
Jun 22, 2010
Start
Feb 2010
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
May 20, 2013
Last update
May 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01148511
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Feb 2010
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
May 20, 2013
Last update
May 30, 2013

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion